|
|
|
30.05.26 - 14:06
|
ENZAMET Trial Shows Veracyte′s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer (Business Wire)
|
|
|
Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease
Additional ASCO data reinforce Decipher Prostate's utility in high-risk localized diseaseSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VCYT #ASCO26--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced results from the ENZAMET trial presented at the 2026 ASCO Annual Meeting. The analysis demonstrates that the Decipher Prostate test identifies which men with metastatic prostate cancer benefit from adding the chemotherapy docetaxel to standard hormonal therapy (ADT plus enzalutamide), known as triplet therapy, and who can safely avoid it, providing the first Level 1B 1 evidence for a genomic test guiding this decision. Complementary data presented at the meeting also reinforce Decipher Prostate's clinical utility in high-risk localized disease.
Approximately 334,000 men are diagnosed with prostate cancer annually in the United States, including about 30,000 who presen...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14.04.26 - 22:09
|
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026 (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
The conference call will be webcast live from the company's website and will be available via the following link: https://edge.media-server.com/mmc/p/293q6w6a. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company's website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering via this link.
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-...
|
|
|
|
|
|
|
|
|
16.03.26 - 21:21
|
Veracyte Names Kevin Haas as Chief Development and Technology Officer (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$VCYT #CancerDiagnostics--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that Kevin Haas, Ph.D., has been appointed Chief Development and Technology Officer, a newly created leadership role designed to advance and scale the company's global product development strategy. Dr. Haas will join Veracyte on March 24, 2026, and he will be responsible for overseeing the company's end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.
As Veracyte's pipeline expands into whole‑genome minimal residual disease (MRD) and other multi‑omics applications, product development requires integrated capabilities across assays, software, AI, and next‑generation informatics to support solutions from diagnosis to disease management. In this role, Dr. Haas will lead these efforts to deliver high‑quality laboratory‑developed tests (LDTs) ...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
